Alternatively, a patient with very slowly progressive Her2-positive breast cancer declining WBRT and starting fam-trastuzumab-deruxtecan-nxki (ENHERTU) could be considered for SL-SRS deferring salvage radiation for a time when the additional lesions might progress. This evidence concerns the gene ERBB2 and breast carcinoma.